# Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers

> **NCT02259881** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 64 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Low dose of BIBT 986 CL, per i.v. infusion
- **DRUG:** Medium dose of BIBT 986 CL, per i.v. infusion
- **DRUG:** High dose of BIBT 986 CL, per i.v. infusion
- **DRUG:** Placebo
- **DRUG:** Lipopolysaccharide (LPS), single i.v. bolus

## Key facts

- **NCT ID:** NCT02259881
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2003-05
- **Final completion:** —
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2014-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02259881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02259881, "Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02259881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*